According to our recent payer coverage analysis for asthma and COPD treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: About 4% of the lives are restricted under commercial and health exchange policies, while about 9% of Medicare beneficiaries are covered.
Trends: The new drugs give payers some cost-saving options and might pull some market share from Advair due to the price difference.